Trial · NCT06123468
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
NCT06123468, Phase 1, Phase 2, Completed, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma. Trials, record NCT06123468. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06123468
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
- NCT number
- NCT06123468
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 58 participants, actual
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Conditions
- Esophagogastric Adenocarcinoma
- Interventions
- Sacituzumab govitecan
- First posted
- 2023-11-08
- Last updated
- 2026-01-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate | up to 12 months | Objective response rate will be assessed according to RECIST v1.1. criteria and is defined as proportion of patients showing complete or partial response (CR+PR). |
| Secondary | Clinical benefit rate | up to 36 months | Clinical benefit rate will be assessed according to RECIST v1.1. criteria and is defined as proportion of patients showing complete response, partial response or stable disease (CR+PR+SD). |
| Secondary | Progression-free survival (PFS) | up to 36 months | Progression-free survival is defined as time from enrollment to the date of progression according to RECIST v1.1 or death due to any cause. Patients who have not experienced an event at the time of analysis will be censored at the most recent date of disease assessment. |
| Secondary | Overall survival (OS) | up to 36 months | Overall survival is defined as the time from enrollment to the date of death from any cause. Patients who have not experienced an event at the time of analysis will be censored at the date when the patient was last known to be alive. |
| Secondary | Safety and toxicity | up to 13 months (max. 12 months treatment plus 30 days after last treatment) | Safety and tolerability assessments will include physical examinations, clinical laboratory profile and continuous assessments of adverse events (AEs). AEs will be monitored throughout the trial and graded in severity according to the guidelines outlined in the NCI CTCAE v5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41648033 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06123468
GET https://conductscience.org/api/trials/v1/NCT06123468/registered